1
|
Martínez A, Infante JR, Quirós J, Rayo JI, Serrano J, Moreno M, Jiménez P, Cobo A, Baena A. Baseline 18F-FDG PET/CT quantitative parameters as prognostic factors in esophageal squamous cell cancer. Rev Esp Med Nucl Imagen Mol 2021; 41:164-170. [PMID: 34452867 DOI: 10.1016/j.remnie.2021.07.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Accepted: 03/18/2021] [Indexed: 11/19/2022]
Abstract
AIM To determine the utility of [18F]FDG PET/CT quantitative parameters as prognostic factors for the response to neoadjuvant treatment, progression-free survival (PFS) and cancer-specific survival (CSS) in patients with esophageal squamous cell carcinoma (SCC). MATERIAL AND METHODS Thirty patients (29 men) diagnosed with SCC were retrospectively evaluated over a 6-year interval. Metabolic parameters were determined: maximum SUV (SUVmax), mean SUV (SUVmed), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) from baseline PET/CT study. After treatment with chemotherapy and/or radiotherapy, response to treatment and patient survival were assessed. The comparison of parameters between groups of responders and non-responders was carried out using a Mann-Whitney U test ROC curves and the Kaplan-Meier method were used for analysis of prognostic factors and survival curves. RESULTS The average follow-up was 22.4 months, with 22 recurrence-progressions and 25 deaths. Significant differences were demonstrated between responders and non-responders with respect to tumor size, MTV and TLG. Survival analysis found significant differences for SCE and CSS depending on these three parameters. CONCLUSION Metabolic parameters MTV and TLG, and tumor size were prognostic factors for neoadjuvant treatment response, PFS, and CSS in patients diagnosed with SCC. Neither SUVmax nor SUVmed were predictive for any of the evaluation criteria. Results could help to personalize patient treatment.
Collapse
Affiliation(s)
- A Martínez
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, Spain.
| | - J R Infante
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, Spain
| | - J Quirós
- Servicio de Oncología Radioterápica, Hospital Universitario de Badajoz, Badajoz, Spain
| | - J I Rayo
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, Spain
| | - J Serrano
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, Spain
| | - M Moreno
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, Spain
| | - P Jiménez
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, Spain
| | - A Cobo
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, Spain
| | - A Baena
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, Spain
| |
Collapse
|
2
|
Martínez A, Infante JR, Quirós J, Rayo JI, Serrano J, Moreno M, Jiménez P, Cobo A, Baena A. Baseline 18F-FDG PET/CT quantitative parameters as prognostic factors in esophageal squamous cell cancer. Rev Esp Med Nucl Imagen Mol 2021; 41:S2253-654X(21)00107-4. [PMID: 34088649 DOI: 10.1016/j.remn.2021.03.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Revised: 03/18/2021] [Accepted: 03/18/2021] [Indexed: 11/20/2022]
Abstract
AIM To determine the utility of 18F-FDG PET/CT quantitative parameters as prognostic factors for the response to neoadjuvant treatment, progression-free survival (PFS) and cancer-specific survival (CSS) in patients with esophageal squamous cell carcinoma (SCC). MATERIAL AND METHODS Thirty patients (29 men) diagnosed with SCC were retrospectively evaluated over a 6-year interval. Metabolic parameters were determined: maximum SUV (SUVmax), mean SUV (SUVmed), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) from baseline PET/CT study. After treatment with chemotherapy and/or radiotherapy, response to treatment and patient survival were assessed. The comparison of parameters between groups of responders and non-responders was carried out using a Mann-Whitney U test. ROC curves and the Kaplan-Meier method were used for analysis of prognostic factors and survival curves. RESULTS The average follow-up was 22.4months, with 22 recurrence-progressions and 25 deads. Significant differences were demonstrated between responders and non-responders with respect to tumor size, MTV and TLG. Survival analysis found significant differences for SCE and CSS depending on these three parameters. CONCLUSION Metabolic parameters MTV and TLG, and tumor size were prognostic factors for neoadjuvant treatment response, PFS, and CSS in patients diagnosed with SCC. Neither SUVmax nor SUVmed were predictive for any of the evaluation criteria. Results could help to personalize patient treatment.
Collapse
Affiliation(s)
- A Martínez
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, España.
| | - J R Infante
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, España
| | - J Quirós
- Servicio de Oncología Radioterápica, Hospital Universitario de Badajoz, Badajoz, España
| | - J I Rayo
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, España
| | - J Serrano
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, España
| | - M Moreno
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, España
| | - P Jiménez
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, España
| | - A Cobo
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, España
| | - A Baena
- Servicio de Medicina Nuclear, Hospital Universitario de Badajoz, Badajoz, España
| |
Collapse
|
3
|
Infante JR, Cabrera J, Rayo JI, Cruz C, Serrano J, Moreno M, Martínez A, Jiménez P, Cobo A. 18F-FDG PET/CT quantitative parameters as prognostic factor in localized and inoperable lung cancer. Rev Esp Med Nucl Imagen Mol 2020; 39:353-359. [PMID: 32605894 DOI: 10.1016/j.remn.2020.05.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2020] [Revised: 05/23/2020] [Accepted: 05/25/2020] [Indexed: 12/25/2022]
Abstract
AIM To assess the utility of 18F-FDG PET/CT quantitative parameters as prognostic factor in patients diagnosed with localized and inoperable lung cancer treated by stereotactic body radiotherapy (SBRT). MATERIAL AND METHODS Fifty patients (42 men) diagnosed in the last 7years with early-stage lung cancer and treated with SBRT alone were assessed by a prospective study. After PET/CT study, metabolic parameters maximum SUV (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were determined at different thresholds. The prognostic factors for overall survival (OS), cause-specific survival (CS) and disease-free survival (DFS) were analysed by Cox proportional hazards model and the survival analysis by Kaplan-Meier method. RESULTS The average follow-up was 39.6months, with 21 recurrences and 24 dead. Univariate analysis determined MTV30 and MTV40 as predictors for OS; MTV30, MTV40, TLG30 and TLG40 for CS, and MTV2, MTV30, MTV40, TLG2, TLG30 and TLG40 for DFS. Survival analysis found statistically significant differences for CS and DFS depending on tumor size and for DFS considering the cut-off values of MTV2 and TLG2 (threshold SUVmax=2). SUVmax, age and sex were not shown to be significant factors. CONCLUSION Pre-treatment quantitative assessment using metabolic parameters MTV2 and TLG2 as well as tumor size proved to be prognostic factors in patients diagnosed with localized and inoperable lung cancer treated by SBRT. Results could help to personalize treatment.
Collapse
Affiliation(s)
- J R Infante
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España.
| | - J Cabrera
- Servicio de Oncología Radioterápica, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - J I Rayo
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - C Cruz
- Servicio de Oncología Radioterápica, Hospital Punta de Europa, Algeciras, Cádiz, España
| | - J Serrano
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - M Moreno
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - A Martínez
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - P Jiménez
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - A Cobo
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| |
Collapse
|
4
|
Italiano A, Infante JR, Shapiro GI, Moore KN, LoRusso PM, Hamilton E, Cousin S, Toulmonde M, Postel-Vinay S, Tolaney S, Blackwood EM, Mahrus S, Peale FV, Lu X, Moein A, Epler J, DuPree K, Tagen M, Murray ER, Schutzman JL, Lauchle JO, Hollebecque A, Soria JC. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. Ann Oncol 2019; 29:1304-1311. [PMID: 29788155 DOI: 10.1093/annonc/mdy076] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Checkpoint kinase 1 (Chk1) inhibition following chemotherapy-elicited DNA damage overrides cell cycle arrest and induces mitotic catastrophe and cell death. GDC-0575 is a highly-selective oral small-molecule Chk1 inhibitor that results in tumor shrinkage and growth delay in xenograft models. We evaluated the safety, tolerability, and pharmacokinetic properties of GDC-0575 alone and in combination with gemcitabine. Antitumor activity and Chk1 pathway modulation were assessed. PATIENTS AND METHODS In this phase I open-label study, in the dose escalation stage, patients were enrolled in a GDC-0575 monotherapy Arm (1) or GDC-0575 combination with gemcitabine Arm (2) to determine the maximum tolerated dose. Patients in arm 2 received either i.v. gemcitabine 1000 mg/m2 (arm 2a) or 500 mg/m2 (arm 2b), followed by GDC-0575 (45 or 80 mg, respectively, as RP2D). Stage II enrolled disease-specific cohorts. RESULTS Of 102 patients treated, 70% were female, the median age was 59 years (range 27-85), and 47% were Eastern Cooperative Oncology Group PS 0. The most common tumor type was breast (37%). The most frequent adverse events (all grades) related to GDC-0575 and/or gemcitabine were neutropenia (68%), anemia (48%), nausea (43%), fatigue (42%), and thrombocytopenia (35%). Maximum concentrations of GDC-0575 were achieved within 2 hours of dosing, and half-life was ∼23 hours. No pharmacokinetic drug-drug interaction was observed between GDC-0575 and gemcitabine. Among patients treated with GDC-0575 and gemcitabine, there were four confirmed partial responses, three occurring in patients with tumors harboring TP53 mutation. Pharmacodynamic data were consistent with GDC-0575 inhibition of gemcitabine-induced expression of pCDK1/2. CONCLUSION GDC-0575 can be safely administered as a monotherapy and in combination with gemcitabine; however, overall tolerability with gemcitabine was modest. Hematological toxicities were frequent but manageable. Preliminary antitumor activity was observed but limited to a small number of patients with a variety of refractory solid tumors treated with GDC-0575 and gemcitabine. CLINICAL TRIAL NUMBER NCT01564251.
Collapse
Affiliation(s)
- A Italiano
- Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France.
| | - J R Infante
- Sarah Cannon Research Institute, Nashville; Tennessee Oncology, Nashville
| | - G I Shapiro
- Early Drug Development Center; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
| | - K N Moore
- Stevenson Oklahoma Cancer Center, Oklahoma City; University of Oklahoma, Oklahoma City
| | - P M LoRusso
- Smilow Cancer Center, New Haven; Yale University, New Haven, USA
| | - E Hamilton
- Sarah Cannon Research Institute, Nashville; Tennessee Oncology, Nashville
| | - S Cousin
- Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France
| | - M Toulmonde
- Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France
| | - S Postel-Vinay
- Départemement d'Innovation Thérapeutique et des Essais Précoces (DITEP), Villejuif; Gustave Roussy, Villejuif; Université Paris Saclay, Villejuif; INSERM, U981, Villejuif, France
| | - S Tolaney
- Early Drug Development Center; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
| | | | - S Mahrus
- Genentech, Inc., South San Francisco, USA
| | - F V Peale
- Genentech, Inc., South San Francisco, USA
| | - X Lu
- Genentech, Inc., South San Francisco, USA
| | - A Moein
- Genentech, Inc., South San Francisco, USA
| | - J Epler
- Genentech, Inc., South San Francisco, USA
| | - K DuPree
- Genentech, Inc., South San Francisco, USA
| | - M Tagen
- Genentech, Inc., South San Francisco, USA
| | - E R Murray
- Genentech, Inc., South San Francisco, USA
| | | | | | - A Hollebecque
- Départemement d'Innovation Thérapeutique et des Essais Précoces (DITEP), Villejuif; Gustave Roussy, Villejuif; Université Paris Saclay, Villejuif
| | | |
Collapse
|
5
|
Liu JF, Moore KN, Birrer MJ, Berlin S, Matulonis UA, Infante JR, Wolpin B, Poon KA, Firestein R, Xu J, Kahn R, Wang Y, Wood K, Darbonne WC, Lackner MR, Kelley SK, Lu X, Choi YJ, Maslyar D, Humke EW, Burris HA. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol 2017; 27:2124-2130. [PMID: 27793850 DOI: 10.1093/annonc/mdw401] [Citation(s) in RCA: 68] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Accepted: 08/16/2016] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND MUC16 is a tumor-specific antigen overexpressed in ovarian (OC) and pancreatic (PC) cancers. The antibody-drug conjugate (ADC), DMUC5754A, contains the humanized anti-MUC16 monoclonal antibody conjugated to the microtubule-disrupting agent, monomethyl auristatin E (MMAE). PATIENTS AND METHODS This phase I study evaluated safety, pharmacokinetics (PK), and pharmacodynamics of DMUC5754A given every 3 weeks (Q3W, 0.3-3.2 mg/kg) or weekly (Q1W, 0.8-1.6 mg/kg) to patients with advanced recurrent platinum-resistant OC or unresectable PC. Biomarker studies were also undertaken. RESULTS Patients (66 OC, 11 PC) were treated with DMUC5754A (54 Q3W, 23 Q1W). Common related adverse events (AEs) in >20% of patients (all grades) over all dose levels were fatigue, peripheral neuropathy, nausea, decreased appetite, vomiting, diarrhea, alopecia, and pyrexia in Q3W patents, and nausea, vomiting, anemia, fatigue, neutropenia, alopecia, decreased appetite, diarrhea, and hypomagnesemia in Q1W patients. Grade ≥3-related AE in ≥5% of patients included neutropenia (9%) and fatigue (7%) in Q3W patients, and neutropenia (17%), diarrhea (9%), and hyponatremia (9%) in Q1W patients. Plasma antibody-conjugated MMAE (acMMAE) and serum total antibody exhibited non-linear PK across tested doses. Minimal accumulation of acMMAE, total antibody, or unconjugated MMAE was observed. Confirmed responses (1 CR, 6 PRs) occurred in OC patients whose tumors were MUC16-positive by IHC (2+ or 3+). Two OC patients had unconfirmed PRs; six OC patients had stable disease lasting >6 months. For CA125, a cut-off of ≥70% reduction was more suitable for monitoring treatment response due to the binding and clearance of serum CA125 by MUC16 ADC. We identified circulating HE4 as a potential novel surrogate biomarker for monitoring treatment response of MUC16 ADC and other anti-MUC16 therapies in OC. CONCLUSIONS DMUC5754A has an acceptable safety profile and evidence of anti-tumor activity in patients with MUC16-expressing tumors. Objective responses were only observed in MUC16-high patients, although prospective validation is required. CLINICAL TRIAL NUMBER NCT01335958.
Collapse
Affiliation(s)
- J F Liu
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - K N Moore
- Division of Gynecologic Oncology, Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City
| | - M J Birrer
- Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston
| | - S Berlin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston.,Department of Oncology, New England Cancer Care Specialists, Kennebunk
| | - U A Matulonis
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - J R Infante
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| | - B Wolpin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - K A Poon
- Early Development, Genentech, South San Francisco, USA
| | - R Firestein
- Early Development, Genentech, South San Francisco, USA
| | - J Xu
- Early Development, Genentech, South San Francisco, USA
| | - R Kahn
- Early Development, Genentech, South San Francisco, USA
| | - Y Wang
- Early Development, Genentech, South San Francisco, USA
| | - K Wood
- Early Development, Genentech, South San Francisco, USA
| | - W C Darbonne
- Early Development, Genentech, South San Francisco, USA
| | - M R Lackner
- Early Development, Genentech, South San Francisco, USA
| | - S K Kelley
- Early Development, Genentech, South San Francisco, USA
| | - X Lu
- Early Development, Genentech, South San Francisco, USA
| | - Y J Choi
- Early Development, Genentech, South San Francisco, USA
| | - D Maslyar
- Early Development, Genentech, South San Francisco, USA
| | - E W Humke
- Early Development, Genentech, South San Francisco, USA
| | - H A Burris
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| |
Collapse
|
6
|
Burris HA, Kurkjian CD, Hart L, Pant S, Murphy PB, Jones SF, Neuwirth R, Patel CG, Zohren F, Infante JR. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies. Cancer Chemother Pharmacol 2017; 80:261-273. [PMID: 28601972 DOI: 10.1007/s00280-017-3343-4] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Accepted: 05/20/2017] [Indexed: 11/28/2022]
Abstract
PURPOSE This phase I trial evaluated the safety, pharmacokinetic profile, and antitumor activity of investigational oral TORC1/2 inhibitor TAK-228 plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies. METHODS Sixty-seven patients received TAK-228 6-40 mg via three dosing schedules; once daily for 3 days (QDx3d QW) or 5 days per week (QDx5d QW), and once weekly (QW) plus paclitaxel 80 mg/m2 (dose-escalation phase, n = 47) and with/without trastuzumab 2 mg/kg (expansion phase, n = 20). Doses were escalated using a modified 3 + 3 design, based upon dose-limiting toxicities in cycle 1. RESULTS TAK-228 pharmacokinetics exhibited dose-dependent increase in exposure when dosed with paclitaxel and no apparent differences when administered with or 24 h after paclitaxel. Dose-limiting toxicities were dehydration, diarrhea, stomatitis, fatigue, rash, thrombocytopenia, neutropenia, leukopenia, and nausea. The maximum tolerated dose of TAK-228 was determined as 10-mg QDx3d QW; the expansion phase proceeded with 8-mg QDx3d QW. Overall, the most common grade ≥3 drug-related toxicities were neutropenia (21%), diarrhea (12%), and hyperglycemia (12%). Of 54 response-evaluable patients, eight achieved partial response and six had stable disease lasting ≥6 months. CONCLUSION TAK-228 demonstrated a safety profile consistent with other TORC inhibitors and promising preliminary antitumor activity in a range of tumor types; no meaningful difference was noted in the pharmacokinetics of TAK-228 when administered with or 24 h after paclitaxel. These findings support further investigation of TAK-228 in combination with other agents including paclitaxel, with/without trastuzumab, in patients with advanced solid tumors. CLINICALTRIALS. GOV IDENTIFIER NCT01351350.
Collapse
Affiliation(s)
- Howard A Burris
- Sarah Cannon Research Institute, 250 25th Avenue North, #100, Nashville, TN, 37203, USA. .,Tennessee Oncology PLLC, Nashville, TN, USA.
| | - C D Kurkjian
- Sarah Cannon Research Institute, 250 25th Avenue North, #100, Nashville, TN, 37203, USA.,Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - L Hart
- Sarah Cannon Research Institute, 250 25th Avenue North, #100, Nashville, TN, 37203, USA.,Florida Cancer Specialists, Fort Myers, FL, USA
| | - S Pant
- Sarah Cannon Research Institute, 250 25th Avenue North, #100, Nashville, TN, 37203, USA.,Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.,The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - P B Murphy
- Sarah Cannon Research Institute, 250 25th Avenue North, #100, Nashville, TN, 37203, USA.,Tennessee Oncology PLLC, Nashville, TN, USA
| | - S F Jones
- Sarah Cannon Research Institute, 250 25th Avenue North, #100, Nashville, TN, 37203, USA
| | - R Neuwirth
- Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
| | - C G Patel
- Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
| | - F Zohren
- Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
| | - J R Infante
- Sarah Cannon Research Institute, 250 25th Avenue North, #100, Nashville, TN, 37203, USA.,Tennessee Oncology PLLC, Nashville, TN, USA
| |
Collapse
|
7
|
DeMichele AM, Harding JJ, Telli ML, Münster P, McKay RR, Iliopoulos O, Whiting S, Orford KW, Bennett MK, Mier JW, Owonikoko TK, Patel MR, Kalinsky K, Carvajal RD, Infante JR, Merit-Bernstam F. Abstract P6-11-05: Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (its) with triple negative breast cancer (TNBC). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-11-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: CB-839 is a first-in-class highly selective inhibitor of GLS, a key enzyme in the utilization of glutamine by cancer cells. TNBC has high GLS expression and is very dependent upon GLS-mediated conversion of glutamine to glutamate for tumor cell growth. CB-839 has antitumor activity in vitro and in vivo in preclinical models of TNBC. Recent studies demonstrate that glutamine utilization can contribute to resistance to paclitaxel, a therapy frequently used to treat TNBC patients. Paclitaxel sensitivity is dependent on down-regulation of the glutamine transporter, SLC1A5, and over-expression of SLC1A5 causes paclitaxel resistance. Consistent with these observations, inhibition of glutamine metabolism with CB-839 has demonstrated strong antitumor activity in combination with paclitaxel.
CX-839-001 is an ongoing Phase 1 trial of CB-839 as monotherapy and in combination with approved agents. We previously reported pharmacodynamic studies demonstrating robust inhibition of GLS in pt blood and tumors and excellent tolerability of CB-839 monotherapy in a variety of tumor types including TNBC. In light of the preclinical rationale and monotherapy tolerability a combination arm was opened testing CB-839 with paclitaxel (Pac-CB) in patients with advanced TNBC. We report here updated results on the Pac-CB dose escalation and expansion cohorts.
Methods: Patients with refractory advanced/metastatic TNBC (prior taxane therapy allowed) received escalating doses of CB-839 (400-800 mg BID) in combination with a fixed weekly Pac dose of 80 mg/m2 Days 1, 8, 15 of a 28 day cycle. Upon demonstration of safety and tolerability, an expansion cohort of TNBC pts was opened.
Results: To date, 15 pts have received Pac-CB at three dose levels of CB-839: 7 pts at 400 mg BID, 5 at 600 mg BID and 3 at 800 mg BID with the latter dose level not completed. 40% of enrolled patients have received >5 prior lines of systemic therapy for adv/met disease, and 10 pts have received prior taxane therapy including 5 in the adv/met setting. The Pac-CB combination has been well tolerated with one DLT during dose escalation (G4 neutropenia at 400 mg BID) and a low rate of dose reductions (2 for Pac and 1 for CB-839). Of 15 pts, the best overall response rate (BORR, see Table) has been PR in 20% (3 pts), SD in 47% (7 pts) and PD in 33% (5 pts) with 5 patients remaining on study. At doses ≥600 mg BID (n=8) the BORR is 38% (3 pts), and disease control rate (CR + PR + SD) is 88% (7 pts). All 3 pts with PRs have received prior Pac, including 2 pts with disease that was refractory to Pac in the advanced/metastatic setting.
Conclusions: The Pac-CB combination has been well tolerated and has demonstrated clinical activity in heavily pre-treated pts with TNBC. At doses ≥600 mg BID, BORR has been 38% and DCR 88%. Notably, PRs have occurred in pts with prior Pac therapy, including 2 pts with Pac-refractory disease in the adv/met setting. Updated data on the escalation and expansion cohorts will be presented.
Dose LevelTotal400 mg BID600 mg BID800 mg BIDRECIST Response Evaluable (N)15753PR3 (20%)02 (40%)1 (33%)SD7 (47%)3 (43%)2 (40%)2 (67%)DCR (CR+PR+SD)10 (67%)3 (43%)4 (80%)3 (100%)PD5 (33%)4 (57%)1 (20%)0
Citation Format: DeMichele AM, Harding JJ, Telli ML, Münster P, McKay RR, Iliopoulos O, Whiting S, Orford KW, Bennett MK, Mier JW, Owonikoko TK, Patel MR, Kalinsky K, Carvajal RD, Infante JR, Merit-Bernstam F. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (its) with triple negative breast cancer (TNBC) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-11-05.
Collapse
Affiliation(s)
- AM DeMichele
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| | - JJ Harding
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| | - ML Telli
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| | - P Münster
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| | - RR McKay
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| | - O Iliopoulos
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| | - S Whiting
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| | - KW Orford
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| | - MK Bennett
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| | - JW Mier
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| | - TK Owonikoko
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| | - MR Patel
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| | - K Kalinsky
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| | - RD Carvajal
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| | - JR Infante
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| | - F Merit-Bernstam
- University of Pennsylvania, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Stanford, CA; University of California, San Francisco, San Francisco, CA; Harvard University, Cambridge, MA; Emory University, Atlanta, GA; Florida Cancer Specialists, Sarasota, FL; Columbia University, New York, NY; Tennessee Oncology, Nashville, TN; University of Texas, Houston, TX; Calithera Biosciences, San Francisco, CA
| |
Collapse
|
8
|
Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol 2016; 27:654-60. [PMID: 26802160 PMCID: PMC4803454 DOI: 10.1093/annonc/mdw006] [Citation(s) in RCA: 73] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Accepted: 12/23/2015] [Indexed: 12/17/2022] Open
Abstract
Any CA19-9 decline at week 8 and radiologic response by week 8 each predicted longer OS in both treatment arms. In the nab-P + Gem arm, the higher proportion of patients with week 8 CA19-9 decrease [82% (206/252); median OS 13.2 months] than a RECIST-defined response [16% (40/252); median OS 13.7 months] suggests that CA19-9 decline is a predictor of OS applicable to a larger population. Background A phase I/II study and subsequent phase III study (MPACT) reported significant correlations between CA19-9 decreases and prolonged overall survival (OS) with nab-paclitaxel plus gemcitabine (nab-P + Gem) treatment for metastatic pancreatic cancer (MPC). CA19-9 changes at week 8 and potential associations with efficacy were investigated as part of an exploratory analysis in the MPACT trial. Patients and methods Untreated patients with MPC (N = 861) received nab-P + Gem or Gem alone. CA19-9 was evaluated at baseline and every 8 weeks. Results Patients with baseline and week-8 CA19-9 measurements were analyzed (nab-P + Gem: 252; Gem: 202). In an analysis pooling the treatments, patients with any CA19-9 decline (80%) versus those without (20%) had improved OS (median 11.1 versus 8.0 months; P = 0.005). In the nab-P + Gem arm, patients with (n = 206) versus without (n = 46) any CA19-9 decrease at week 8 had a confirmed overall response rate (ORR) of 40% versus 13%, and a median OS of 13.2 versus 8.3 months (P = 0.001), respectively. In the Gem-alone arm, patients with (n = 159) versus without (n = 43) CA19-9 decrease at week 8 had a confirmed ORR of 15% versus 5%, and a median OS of 9.4 versus 7.1 months (P = 0.404), respectively. In the nab-P + Gem and Gem-alone arms, by week 8, 16% (40/252) and 6% (13/202) of patients, respectively, had an unconfirmed radiologic response (median OS 13.7 and 14.7 months, respectively), and 79% and 84% of patients, respectively, had stable disease (SD) (median OS 11.1 and 9 months, respectively). Patients with SD and any CA19-9 decrease (158/199 and 133/170) had a median OS of 13.2 and 9.4 months, respectively. Conclusion This analysis demonstrated that, in patients with MPC, any CA19-9 decrease at week 8 can be an early marker for chemotherapy efficacy, including in those patients with SD. CA19-9 decrease identified more patients with survival benefit than radiologic response by week 8.
Collapse
Affiliation(s)
- E G Chiorean
- Department of Medicine/Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle
| | - D D Von Hoff
- HonorHealth and The Translational Genomics Research Institute (TGen), Scottsdale, USA
| | - M Reni
- Department of Radiation Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - F P Arena
- Department of Oncology, NYU Langone Arena Oncology, Lake Success
| | - J R Infante
- Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville
| | - V G Bathini
- Cancer Center of Excellence, University of Massachusetts Medical School, Worcester
| | - T E Wood
- UAB Comprehensive Cancer Center, Birmingham, USA
| | - P N Mainwaring
- Mater Private Centre for Haematology & Oncology, South Brisbane, Australia
| | - R T Muldoon
- Department of Oncology, Genesis Cancer Center, Hot Springs, USA
| | - P R Clingan
- Southern Medical Day Care Centre, Wollongong, Australia
| | - V Kunzmann
- Medizinische Klinik und Poliklinik II, University of Wuerzburg, Wuerzburg, Germany
| | - R K Ramanathan
- HonorHealth and The Translational Genomics Research Institute (TGen), Scottsdale, USA
| | - J Tabernero
- Medical of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - D Goldstein
- Department of Oncology, Prince of Wales Hospital, Sydney, Australia
| | | | - B Lu
- Celgene Corporation, Summit, USA
| | - A Ko
- Celgene Corporation, Summit, USA
| |
Collapse
|
9
|
Domínguez ML, Rayo JI, Serrano J, Infante JR, García L, Moreno M. Uncommon isolated distant subcutaneous tissue and skeletal muscle metastasis from oesophageal cancer diagnosed by PET/CT (18)F-FDG. Rev Esp Med Nucl Imagen Mol 2015; 35:38-41. [PMID: 26260890 DOI: 10.1016/j.remn.2015.07.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2015] [Revised: 07/03/2015] [Accepted: 07/03/2015] [Indexed: 12/28/2022]
Abstract
Distant soft-tissue metastases (subcutaneous tissues and skeletal muscle) are extremely rare, particularly in oesophageal carcinoma. The case is described of a patient who was treated for oesophageal adenocarcinoma 2.5 years previously. A PET/CT was performed showing metastatic spread due to a solitary focus of increased tracer uptake corresponding to one subcutaneous node in the upper abdomen. An excisional biopsy showed a metastasis from the carcinoma. Restaging PET/CT (18)F-FDG study was performed 2 year later, demonstrating foci of increased uptake within several muscles as isolated distant haematogenous spread of metastases, histopathologically confirmed. As most of soft-tissue metastases are asymptomatic, the physicians should recommend a histopathological study of focal FDG uptake at subcutaneous tissues and/or skeletal muscles, because they may be the first sign of disease spread, so therapeutic management of these patients could be changed.
Collapse
Affiliation(s)
- M L Domínguez
- Servicio de Medicina Nuclear, Hospital Universitario «Infanta Cristina», Badajoz, España.
| | - J I Rayo
- Servicio de Medicina Nuclear, Hospital Universitario «Infanta Cristina», Badajoz, España
| | - J Serrano
- Servicio de Medicina Nuclear, Hospital Universitario «Infanta Cristina», Badajoz, España
| | - J R Infante
- Servicio de Medicina Nuclear, Hospital Universitario «Infanta Cristina», Badajoz, España
| | - L García
- Servicio de Medicina Nuclear, Hospital Universitario «Infanta Cristina», Badajoz, España
| | - M Moreno
- Servicio de Medicina Nuclear, Hospital Universitario «Infanta Cristina», Badajoz, España
| |
Collapse
|
10
|
Infante JR, Lorente R, Rayo JI, Serrano J, Domínguez ML, García L, Moreno M. [Use of radioguided surgery in the surgical treatment of osteoid osteoma]. Rev Esp Med Nucl Imagen Mol 2015; 34:225-9. [PMID: 25743036 DOI: 10.1016/j.remn.2015.01.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2014] [Revised: 01/22/2015] [Accepted: 01/24/2015] [Indexed: 10/23/2022]
Abstract
OBJECTIVE Osteoid osteoma is the third most common benign bone tumor and complete surgical resection is definitive treatment. There are a limited number of publications on the use of radioguided surgery in this type of lesion. To assess the utility of radioguided surgery in our environment as a method of surgical treatment of this tumor. MATERIAL AND METHODS We retrospectively evaluated 12 patients (2 women and 10 men, age range 9-44 years) with clinical and radiological suspicion of osteoid osteoma. Bone scintigraphy showed foci of pathology uptake compatible with suspected lesion in the femur (4 cases), tibia (3), vertebral column (3), humerus (1) and talus (1). Subsequently patients underwent surgical treatment by radioguided surgery after injection of a dose of (99m)Tc-hydroxy diphosphonate. The nidus was removed using gamma probe and mini gamma camera, considering the technique to be completed when its counts decreased to the levels of the surrounding bone counts. RESULTS Lesions were located in all patients (12 of 12), and were confirmed histologically in 8 of them, including an osteoblastoma. The cure rate was 100%, based on the disappearance of pain after a minimum follow-up of 6 months. CONCLUSION Use of radioguided surgery in the surgical treatment of osteoid osteoma showed satisfactory results, with 100% efficiency in both lesion location and outcome of treatment and without major postoperative complications.
Collapse
Affiliation(s)
- J R Infante
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España.
| | - R Lorente
- Servicio de Traumatología, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - J I Rayo
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - J Serrano
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - M L Domínguez
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - L García
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - M Moreno
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| |
Collapse
|
11
|
Tolcher AW, Bendell JC, Papadopoulos KP, Burris HA, Patnaik A, Jones SF, Rasco D, Cox DS, Durante M, Bellew KM, Park J, Le NT, Infante JR. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Ann Oncol 2015; 26:58-64. [PMID: 25344362 DOI: 10.1093/annonc/mdu482] [Citation(s) in RCA: 96] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND This phase Ib trial investigated the safety, tolerability, and recommended phase II dose and schedule of the MEK inhibitor trametinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus. Secondary objectives included pharmacokinetic (PK) characterization and evaluation of clinical activity. PATIENTS AND METHODS A total of 67 patients with advanced solid tumors were enrolled in this open-label, single-arm, dose-escalation study. Dose escalation followed a 3 + 3 design. Patients were assigned to one of 10 different cohorts, involving either daily dosing with both agents or daily dosing with trametinib and intermittent everolimus dosing. This included an expansion cohort comprising patients with pancreatic tumors. PKs samples were collected predose, as well as 1, 2, 4, and 6 h post-dose on day 15 of the first treatment cycle. RESULTS Concurrent treatment with trametinib and everolimus resulted in frequent treatment-related adverse events, including mucosal inflammation (40%), stomatitis (25%), fatigue (54%), and diarrhea (42%). PK assessment did not suggest drug-drug interactions between these two agents. Of the 67 enrolled patients, 5 (7%) achieved partial response (PR) to treatment and 21 (31%) displayed stable disease (SD). Among the 21 patients with pancreatic cancer, PR was observed in 1 patient (5%) and SD in 6 patients (29%). CONCLUSIONS This study was unable to identify a recommended phase II dose and schedule of trametinib in combination with everolimus that provided an acceptable tolerability and adequate drug exposure.
Collapse
Affiliation(s)
- A W Tolcher
- South Texas Accelerated Research Therapeutics LLC, San Antonio.
| | - J C Bendell
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| | | | - H A Burris
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| | - A Patnaik
- South Texas Accelerated Research Therapeutics LLC, San Antonio
| | - S F Jones
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| | - D Rasco
- South Texas Accelerated Research Therapeutics LLC, San Antonio
| | - D S Cox
- GlaxoSmithKline, Collegeville
| | | | - K M Bellew
- Pharmaceutical Companies of Johnson and Johnson, Greater Philadelphia Area
| | - J Park
- GlaxoSmithKline, Collegeville
| | - N T Le
- Novartis, East Hanover, USA
| | - J R Infante
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| |
Collapse
|
12
|
Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, Long GV, Daud A. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann Oncol 2014; 26:415-21. [PMID: 25411413 DOI: 10.1093/annonc/mdu529] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Pyrexia is a frequent adverse event with combined dabrafenib and trametinib therapy (CombiDT), but little is known of its clinical associations, etiology, or appropriate management. PATIENTS AND METHODS All patients on the BRF133220 phase I/II trial of CombiDT treated at the standard dose (150/2) were included for assessment of pyrexia (n = 201). BRAF and MEK inhibitor-naïve patients (n = 117) were included for efficacy analyses. Pyrexia was defined as temperature ≥38°C (≥100.4(°)F) or related symptoms. RESULTS Fifty-nine percent of patients developed pyrexia during treatment, 24% of which had pyrexia symptoms without a recorded elevation in body temperature. Pyrexia was grade 2+ in 60% of pyrexia patients. Median time to onset of first pyrexia was 19 days, with a median duration of 9 days. Pyrexia patients had a median of two pyrexia events, but 21% had three or more events. Various pyrexia management approaches were conducted in this study. A trend was observed between dabrafenib and hydroxy-dabrafenib exposure and pyrexia. No baseline clinical characteristics predicted pyrexia, and pyrexia was not statistically significantly associated with treatment outcome. CONCLUSIONS Pyrexia is a frequent and recurrent toxicity with CombiDT treatment. No baseline features predict pyrexia, and it is not associated with clinical outcome. Dabrafenib and metabolite exposure may contribute to the etiology of pyrexia. The optimal secondary prophylaxis for pyrexia is best studied in a prospective trial.
Collapse
Affiliation(s)
- A M Menzies
- Melanoma Institute Australia and The University of Sydney, Sydney, Australia
| | - M T Ashworth
- University of California San Francisco, San Francisco
| | - S Swann
- Clinical Statistics, GlaxoSmithKline, Collegeville, USA
| | - R F Kefford
- Melanoma Institute Australia and The University of Sydney, Sydney, Australia Westmead Hospital, University of Sydney, Sydney Westmead Millennium Institute, University of Sydney, Sydney, Australia
| | - K Flaherty
- Massachusetts General Hospital Center, Boston
| | - J Weber
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa
| | - J R Infante
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| | - K B Kim
- California Pacific Medical Center, San Francisco
| | - R Gonzalez
- Department of Medical Oncology, The University of Colorado Cancer Center, Aurora
| | - O Hamid
- Department of Oncology, The Angeles Clinic and Research Institute, Santa Monica
| | - L Schuchter
- Penn Medicine, The University of Pennsylvania, Philadelphia, USA
| | - J Cebon
- Oncology Unit, Ludwig Institute for Cancer Research, Heidelberg, Australia
| | - J A Sosman
- Department of Oncology, Vanderbilt University Medical Centre, Nashville, USA
| | - S Little
- Clinical Statistics, GlaxoSmithKline, Collegeville, USA
| | - P Sun
- Clinical Statistics, GlaxoSmithKline, Collegeville, USA
| | - G Aktan
- Clinical Statistics, GlaxoSmithKline, Collegeville, USA
| | - D Ouellet
- Clinical Statistics, GlaxoSmithKline, Collegeville, USA
| | - F Jin
- Clinical Statistics, GlaxoSmithKline, Collegeville, USA
| | - G V Long
- Melanoma Institute Australia and The University of Sydney, Sydney, Australia Westmead Millennium Institute, University of Sydney, Sydney, Australia
| | - A Daud
- University of California San Francisco, San Francisco
| |
Collapse
|
13
|
Infante JR, Rayo JI, Serrano J, Domínguez ML, García L, Durán C, Moreno M. [Clinical application of ROLL technique in non-breast diseases. Complementary use after PET-CT study]. Rev Esp Med Nucl Imagen Mol 2014; 34:162-6. [PMID: 25304844 DOI: 10.1016/j.remn.2014.08.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Revised: 08/07/2014] [Accepted: 08/10/2014] [Indexed: 11/24/2022]
Abstract
OBJECTIVE The aim of this study was to evaluate the usefulness of ROLL technique (Radioguided Occult Lesion Localization) as a verification method of suspicious lesions not related to breast disease found in PET-CT studies. MATERIAL AND METHODS We retrospectively evaluated 9 patients diagnosed of cancer or with suspected tumor disease who showed hypermetabolic lymph nodes in (18)F-FDG PET-CT. Subjects underwent diagnostic testing for evaluation of treatment response in lymphoma (3), suspected recurrence in other tumors (3) or biopsy guide (3). The study group consisted of 4 women and 5 men, age range 25-72 years. ROLL technique was performed in surgically accessible lesions (supraclavicular region, lateral cervical, axillary and inguinal) with an intralesional injection of (99m)Tc-albumin macroaggregates guided by ultrasound the day before surgery. A scintigraphic study confirmed the focal tracer deposit and absence of skin contamination. During surgery, a gamma probe and portable gammacamera were used to locate lymph nodes. RESULTS Surgical localization of radiolabeled lymph nodes was achieved in all cases with minimally invasive surgery and few postoperative complications. Histological study resulted in five tumor involvement (3 lymphoma, 1 germ cell tumor and 1 neuroendocrine carcinoma) and confirmed the existence of four false-positives in PET-CT study (1 sarcoidosis and 3 reactive follicular hyperplasia). CONCLUSION The ROLL technique proved to be a useful and relatively simple method for the study of no breast lesions suspicious of malignancy in PET-CT study.
Collapse
Affiliation(s)
- J R Infante
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España.
| | - J I Rayo
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - J Serrano
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - M L Domínguez
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - L García
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - C Durán
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - M Moreno
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| |
Collapse
|
14
|
Rini B, Redman B, Garcia JA, Burris HA, Li S, Fandi A, Beck R, Jungnelius U, Infante JR. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. Ann Oncol 2014; 25:1794-1799. [PMID: 24914044 PMCID: PMC4311191 DOI: 10.1093/annonc/mdu212] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2014] [Revised: 05/27/2014] [Accepted: 06/02/2014] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND This phase I/II study was conducted to determine the maximum tolerated dose (MTD), safety, and efficacy of lenalidomide plus sunitinib in metastatic renal cell carcinoma (RCC) patients. PATIENTS AND METHODS Patients with histologically confirmed, metastatic RCC were treated with 10 mg/day lenalidomide plus 37.5 mg/day sunitinib, orally in 21-day cycles. Doses were escalated to determine the MTD in phase I, with additional patients planned at this dose in phase II. Primary end points were MTD and response rate. RESULTS Sixteen patients received a median of 2, 3, and 5 cycles in cohort 1 [lenalidomide 10 mg (days 1-21) and sunitinib 37.5 mg (days 1-21)], cohort 2 [lenalidomide 10 mg (days 1-21) and sunitinib 37.5 mg (days 1-14)], and cohort 3 [lenalidomide 15 mg (days 1-21) and sunitinib 37.5 mg (days 1-14)], respectively. Median treatment durations were 41, 63, and 97 days for lenalidomide; and 41, 57, and 97.5 days for sunitinib. The MTD was found to be continuous dosing of lenalidomide 10 mg/day plus sunitinib 37.5 mg/day for 14 of 21 days. Dose-limiting toxicities included neutropenia, leukopenia, thrombocytopenia, asthenia, atrial fibrillation, and increased transaminases. The most frequent grade 3-4 treatment-emergent adverse events were hematologic, including neutropenia and leukopenia. One patient achieved partial response, and seven had stable disease of which three were confirmed at subsequent tumor assessments. B cells and several T-cell subsets were modulated versus baseline. CONCLUSION The dose schedules of lenalidomide and sunitinib evaluated in this study were not well tolerated; cumulative toxicity precluded enrollment at the MTD.
Collapse
Affiliation(s)
- B Rini
- Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urological Institute, Cleveland.
| | - B Redman
- Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor
| | - J A Garcia
- Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urological Institute, Cleveland
| | - H A Burris
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| | | | | | | | | | - J R Infante
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| |
Collapse
|
15
|
Pant S, Saleh M, Bendell J, Infante JR, Jones S, Kurkjian CD, Moore KM, Kazakin J, Abbadessa G, Wang Y, Chen Y, Schwartz B, Camacho LH. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. Ann Oncol 2014; 25:1416-1421. [PMID: 24737778 DOI: 10.1093/annonc/mdu157] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND Tivantinib (ARQ 197) is an orally available, non-adenosine triphosphate competitive, selective c-MET inhibitor. The primary objective of this study was to evaluate the safety, tolerability and to establish the recommended phase II dose (RP2D) of tivantinib and gemcitabine combination. PATIENTS AND METHODS Patients with advanced or metastatic solid tumors were treated with escalating doses of tivantinib (120-360 mg capsules) in combination with gemcitabine (1000 mg/m(2) weekly for 3 of 4 weeks). Different schedules of administration were tested and modified based on emerging preclinical data. Tivantinib was given continuously, twice a day (b.i.d.) for 2, 3 or 4 weeks of a 28-day cycle or on a 5-day on, 2-day off schedule (the day before and day of gemcitabine administration). RESULTS Twenty-nine patients were treated with gemcitabine and escalating doses of tivantinib: 120 mg b.i.d. (n = 4), 240 mg b.i.d. (n = 6) and 360 mg b.i.d. (n = 19). No dose-limiting toxicities were observed in escalation. The RP2D was 360 mg b.i.d. daily, and 45 additional patients were enrolled in the expansion cohort. Grade ≥3 treatment-related toxicities were observed in 54 of 74 (73%) patients with the most common being neutropenia (43%), anemia (30%), thrombocytopenia (28%) and fatigue (15%). There was one treatment-related death due to neutropenia. Administration of gemcitabine did not affect tivantinib concentration. Fifty-six patients were assessable for response. Eleven (20%) patients achieved a partial response and 26 (46%) had stable disease (SD), including 15 (27%) who achieved SD for over 4 months. Ten of 37 patients with clinical benefit had prior exposure to gemcitabine. CONCLUSION The combination of tivantinib at its monotherapy dose and standard dose gemcitabine was safe and tolerable. Early signs of antitumor activity may warrant further development of this combination in nonsmall-cell lung cancer, ovarian, pancreatic and cholangiocarcinoma. CLINICALTRIALSGOV IDENTIFIER NCT00874042.
Collapse
Affiliation(s)
- S Pant
- University of Oklahoma Health Sciences Center, Oklahoma City.
| | - M Saleh
- Georgia Cancer Specialists, Atlanta
| | - J Bendell
- SCRI, Tennessee Oncology, PLLC, Nashville
| | | | - S Jones
- SCRI, Tennessee Oncology, PLLC, Nashville
| | - C D Kurkjian
- University of Oklahoma Health Sciences Center, Oklahoma City
| | - K M Moore
- University of Oklahoma Health Sciences Center, Oklahoma City
| | | | | | | | - Y Chen
- BioMarin Pharmaceutical, Inc., Novato
| | | | | |
Collapse
|
16
|
Domínguez M, Rayo J, Serrano J, Sánchez R, Infante JR, García L, Durán C. Vertebral hemangioma: "Cold" vertebrae on bone scintigraphy and fluordeoxy-glucose positron emission tomography-computed tomography. Indian J Nucl Med 2013; 26:49-51. [PMID: 21969784 PMCID: PMC3180726 DOI: 10.4103/0972-3919.84617] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Bone hemangiomas are benign and infrequent lesions. At Tc-99m bone scintigraphy they show variable degrees of radiotracer uptake and even absence of it. At fluordeoxy-glucose (FDG) Positron Emission Tomography-Computed Tomography (PET/CT), hemangioma is one of the causes of “cold” vertebrae, apart from postexternal radiotherapy. We present a woman diagnosed of breast carcinoma, with a photopenic defect at a thoracic vertebrae at Tc-99m bone scan. In order to rule out bone lytic metastasis, a FDG PET/CT was performed showing a “cold” vertebrae too. Findings were highly suggestive of vertebral hemangioma, that was confirmed by magnetic resonance imaging.
Collapse
Affiliation(s)
- Ml Domínguez
- Department of Nuclear Medicine, Hospital Universitario "Infanta Cristina", Badajoz, Spain.
| | | | | | | | | | | | | |
Collapse
|
17
|
Dienstmann R, Vidal L, Dees EC, Chia S, Mayer EL, Porter D, Baney T, Dhuria S, Sen SK, Firestone B, Papoutsakis D, Cameron S, Infante JR. Abstract P6-11-06: A phase Ib study of LCL161, an oral inhibitor of apoptosis (IAP) antagonist, in combination with weekly paclitaxel in patients with advanced solid tumors. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-11-06] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Impaired apoptosis is a common feature of cancer cells and may contribute to chemoresistance. LCL161 is an oral small molecule antagonist of Inhibitor of Apoptosis Proteins (IAPs) that sensitizes a subset of tumors from diverse lineages to treatment with cytotoxic therapies, including paclitaxel. Multiple breast cancer models are sensitive to LCL161 as a single agent and LCL161 acts synergistically with paclitaxel in these models. A phase I study established an LCL161 dose of 1800 mg once weekly as well tolerated, with strong evidence of pharmacodynamic activity at doses ≥320 mg. This ongoing phase Ib study defines the dose limiting toxicities (DLTs), maximum tolerated dose (MTD), safety, and pharmacokinetics (PK) of LCL161 in combination with weekly paclitaxel.
Methods: Patients with advanced/metastatic solid tumors were treated with paclitaxel 80 mg/m2 each week followed by escalating doses of LCL161 administered once weekly immediately following paclitaxel. PK and biomarker sampling was performed.
Results: Thirty-two patients have received LCL161 doses of 600 mg (n = 3), 1200 mg (n = 5), 1500 mg (n = 4), and 1800 mg (n = 20). The most frequent adverse events considered LCL161-related included diarrhea (n = 11; 1 Grade 3), nausea (n = 8), fatigue (n = 7; 2 Grade 3), peripheral neuropathy (n = 6; 1 Grade 3), vomiting (n = 6), decreased appetite (n = 5), alopecia (n = 4), and anemia (n = 4). The principal DLTs were neutropenia, fatigue, and neuropathy. Significant cytokine release syndrome, the DLT of single-agent LCL161, has not been observed likely due to the use of dexamethasone as a premedication. No PK interaction between LCL161 and paclitaxel was observed. RECIST partial responses have been observed in 4 patients with diverse tumor types, including breast cancer. Preliminary antitumor activity in the expansion cohort with breast cancer patients will be presented.
Discussion: LCL161 and paclitaxel combination therapy is well tolerated, with manageable toxicities and no evidence of a PK interaction that might interfere with the activity of either agent. Enrollment of additional patients with breast and ovarian cancer into an expansion cohort is ongoing, utilizing an approach to identify those more likely to respond to treatment with IAP antagonists.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-11-06.
Collapse
Affiliation(s)
- R Dienstmann
- Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Novartis Pharmaceuticals Corporation, Cambridge, MA; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Sarah Canon Research Institute, Nashville, TN
| | - L Vidal
- Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Novartis Pharmaceuticals Corporation, Cambridge, MA; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Sarah Canon Research Institute, Nashville, TN
| | - EC Dees
- Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Novartis Pharmaceuticals Corporation, Cambridge, MA; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Sarah Canon Research Institute, Nashville, TN
| | - S Chia
- Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Novartis Pharmaceuticals Corporation, Cambridge, MA; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Sarah Canon Research Institute, Nashville, TN
| | - EL Mayer
- Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Novartis Pharmaceuticals Corporation, Cambridge, MA; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Sarah Canon Research Institute, Nashville, TN
| | - D Porter
- Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Novartis Pharmaceuticals Corporation, Cambridge, MA; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Sarah Canon Research Institute, Nashville, TN
| | - T Baney
- Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Novartis Pharmaceuticals Corporation, Cambridge, MA; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Sarah Canon Research Institute, Nashville, TN
| | - S Dhuria
- Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Novartis Pharmaceuticals Corporation, Cambridge, MA; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Sarah Canon Research Institute, Nashville, TN
| | - SK Sen
- Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Novartis Pharmaceuticals Corporation, Cambridge, MA; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Sarah Canon Research Institute, Nashville, TN
| | - B Firestone
- Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Novartis Pharmaceuticals Corporation, Cambridge, MA; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Sarah Canon Research Institute, Nashville, TN
| | - D Papoutsakis
- Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Novartis Pharmaceuticals Corporation, Cambridge, MA; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Sarah Canon Research Institute, Nashville, TN
| | - S Cameron
- Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Novartis Pharmaceuticals Corporation, Cambridge, MA; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Sarah Canon Research Institute, Nashville, TN
| | - JR Infante
- Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Novartis Pharmaceuticals Corporation, Cambridge, MA; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Sarah Canon Research Institute, Nashville, TN
| |
Collapse
|
18
|
Infante JR, Reyes C, Ramos M, Rayo JI, Lorente R, Serrano J, Domínguez ML, García L, Durán C, Sánchez R. The usefulness of densitometry as a method of assessing the nutritional status of athletes. Comparison with body mass index. Rev Esp Med Nucl Imagen Mol 2012; 32:281-5. [PMID: 23164671 DOI: 10.1016/j.remn.2012.09.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2012] [Revised: 09/19/2012] [Accepted: 09/23/2012] [Indexed: 11/26/2022]
Abstract
UNLABELLED The body mass index (BMI) is used to assess nutritional status. The result in athletes may be overestimated due to increase in muscle mass. OBJECTIVE To assess the usefulness of fat mass index (FMI) and lean mass index (LMI) determination as indicators of nutritional status and to compare the results with BMI. MATERIAL AND METHODS We studied 28 amateur rugby players, male. After being subjected to whole body densitometry by dual X-ray absorptiometry, we determined fat and lean body mass together with other parameters. FMI (fat in kg/height in meters(2)), LMI (lean in kg/height in meters(2)) and appendicular muscle mass index (AMMI, arms and legs musculature in kg/height in meters(2)) were calculated. RESULTS Using BMI, 18 players were overweight and 4 obese type I. Considering FMI, 7 of them had normal values and high LMI and AMMI, one of them changed from overweight to obese and another one from obese to overweight. Of the 6 players with normal BMI, one of them showed fat excess and another one fat defect. The results changed the assessment of nutritional status in 39% of players. CONCLUSIONS Although BMI is an appropriate parameter in general population for the assessment of nutritional status, in athletes should be taken into account fat and muscle body percentage and their corresponding indexes. The whole body densitometry appears to be a simple and reliable technique for this purpose.
Collapse
Affiliation(s)
- J R Infante
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, España.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Infante JR, García L, Laguna P, Durán C, Rayo JI, Serrano J, Domínguez ML, Sánchez R. Lymphoscintigraphy for differential diagnosis of peripheral edema: diagnostic yield of different scintigraphic patterns. Rev Esp Med Nucl Imagen Mol 2012; 31:237-42. [PMID: 23067524 DOI: 10.1016/j.remn.2011.11.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2011] [Revised: 11/20/2011] [Accepted: 11/21/2011] [Indexed: 10/28/2022]
Abstract
UNLABELLED Edema of the limbs is a common reason for medical consultation, for which the lymphoscintigraphy is considered to be a reliable method for its differential diagnosis. OBJECTIVE To evaluate the usefulness of radionuclide studies in the differential diagnosis of edema, and the diagnostic yield of different scintigraphic patterns. MATERIAL AND METHODS A total of 61 patients, mean age 43 years, referred to our Department in the last three years for suspected lymphoedema, were considered. One patient was discarded due to lack of diagnosis, 56 had lower limb edema and 4 upper limb edema. After intradermal injection of two doses of (99m)Tc-nanocolloid, scintigraphic scans were made at 30 and 120minutes. The final diagnosis was based on imaging tests, clinical course, and response to treatment. We calculated the parameters of the diagnostic yield of four different scintigraphic patterns (presence of dermal backflow, asymmetry-alteration in inguinal/axillary nodes, presence of collateral pathways, and visualization of intermediate lymph nodes), considering them individually and jointly. RESULTS The best diagnostic yield was achieved by considering dermal backflow and asymmetry in inguinal/axillary nodes (accuracy 88.9%, specificity 96.4%, PPV 95.5%). Evaluation of intermediate lymph nodes and presence of collateral pathways contributed little to the diagnostic yield, showing poor sensitivity and high false positive rates. CONCLUSION The lymphoscintigraphy had high diagnostic yield, allowing early treatment of lymphœdema. The dermal backflow and asymmetry in inguinal/axillary nodes had the greatest diagnostic accuracy. Evaluation of intermediate lymph nodes and visualization of collateral pathways contributed little to improving the diagnosis.
Collapse
Affiliation(s)
- J R Infante
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Infante JR, Falchook GS, Lawrence DP, Weber JS, Kefford RF, Bendell JC, Kurzrock R, Shapiro G, Kudchadkar RR, Long GV, Burris HA, Kim KB, Clements A, Peng S, Yi B, Allred AJ, Ouellet D, Patel K, Lebowitz PF, Flaherty KT. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.18_suppl.cra8503] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CRA8503 Background: In preclinical models, the BRAF/MEK inhibitor (i) combination GSK436/GSK212 has demonstrated enhanced activity against BRAF-mutant cancer cells compared to either drug alone, delayed emergence of GSK436 resistance, and prevented proliferative skin lesions attributable to BRAFi exposure. Methods: Eligible patients (pts) had BRAF V600 mutation positive solid tumors. Part 1: pharmacokinetic (PK) drug-drug interaction (DDI) study. Part 2: Dose escalation of continuous daily dosing of the combination followed by expansion cohorts; Part 3: Randomized phase II trial in untreated stage IV melanoma. Results: 45 pts have received ≥ 1 dose of GSK212 + GSK436, including 43 melanoma (all BRAFi naïve), 1 NSCLC and 1 salivary duct carcinoma. PK results of 7 pts in Part 1 showed no effect of GSK212 on single dose of GSK436. There was no clinically meaningful DDI between GSK436 and GSK212 after repeat dosing of the combination (Part 2). GSK436 was dosed 75-150 mg BID in combination with GSK212 1.0, 1.5, 2.0 mg QD. The recommended dose was 2 mg QD GSK212 in combination with 150 mg BID GSK436. At 1.5 mg GSK212, there was one DLT, a recurrent grade (G) 2 neutrophilic panniculitis. The only G4 adverse event (AE) was a sepsis-like syndrome with fever/hypotension. G3 AEs included generalized rash (n=2, 4%) and neutropenia (n=2, 4%). Skin toxicity ≥ G2 occurred in 9 (20%) pts; of these, G2 rash (n=4, 8%) and G2 macular rash (n=1, 2%). No cutaneous squamous cell carcinoma (SCC) or hyperproliferative skin lesions have occurred at any dose level. Other common G2 toxicities were pyrexia (n=5, 11%), vomiting (n=2, 4%) and fatigue (n=2, 4%). Of 16 evaluable pts in Part 2, 13 pts had PR and 3 SD for an ORR of 81% (95% CI 54.4%-96.0%) and all but 2 pts remain on study. In 10 evaluable pts who received 150 mg BID GSK436 + ≥1 mg QD GSK212, 9 pts had PR and 1 SD. Conclusions: GSK212 at 2 mg QD combines safely with GSK436 150 mg BID, no SCC thus far and decreased frequency of rash compared to previous trials of single agent GSK436 and GSK212, respectively. The preliminary anti-tumor activity warrants further investigation; the randomized phase II trial (Part 3) is accruing.
Collapse
Affiliation(s)
- J. R. Infante
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - G. S. Falchook
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - D. P. Lawrence
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - J. S. Weber
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - R. F. Kefford
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - J. C. Bendell
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - R. Kurzrock
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - G. Shapiro
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - R. R. Kudchadkar
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - G. V. Long
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - H. A. Burris
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - K. B. Kim
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - A. Clements
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - S. Peng
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - B. Yi
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - A. J. Allred
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - D. Ouellet
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - K. Patel
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - P. F. Lebowitz
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| | - K. T. Flaherty
- The Sarah Cannon Cancer Center, Nashville, TN; University of Texas M. D. Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Boston, MA; Moffitt Cancer Center, Tampa, FL; Melanoma Institute Australia, Westmead Institute for Cancer Research, University of Sydney at Westmead Hospital, Sydney, Australia; Sarah Cannon Research Institute, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Royal Prince Alfred
| |
Collapse
|
21
|
Domínguez ML, Lorente R, Rayo JI, Serrano J, Sánchez R, Infante JR, García L, Durán C. SPECT-CT with 67Ga-citrate in the management of spondylodiscitis. Rev Esp Med Nucl Imagen Mol 2011; 31:34-9. [PMID: 21658818 DOI: 10.1016/j.remn.2011.04.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2011] [Revised: 04/08/2011] [Accepted: 04/18/2011] [Indexed: 11/19/2022]
Abstract
Spondylodiscitis affects a small proportion of all patients with locomotor system infections, however its early diagnosis is important due to its potential morbidity. Magnetic resonance imaging is the diagnostic method of choice. Nonetheless, it has certain limitations and is not suitable for all patients. The conventional scintigraphic studies for evaluating spondylodiscitis are those performed with (99m)Tc-HDP and (67)Ga-citrate. However, their poor image resolution is a disadvantage of these techniques. The use of hybrid Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) improves detection of the disease by combining functional and anatomical images. We present 9 patients with suspicion of spondylodiscitis who underwent sequential bone scintigraphy with (99m)Tc-HDP and SPECT-CT with (67)Ga-citrate, with positive findings confirmed by clinical monitoring for at least 6 months.
Collapse
Affiliation(s)
- M L Domínguez
- Servicio de Medicina Nuclear, Hospital Universitario Infanta Cristina, Badajoz, España.
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, Wu K, Skolnik JM, Hylander-Gans L, Osmukhina A, Huszar D, Herbst RS. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 69:165-72. [PMID: 21638123 DOI: 10.1007/s00280-011-1667-z] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2011] [Accepted: 05/02/2011] [Indexed: 12/30/2022]
Abstract
PURPOSE Inhibition of kinesin spindle protein or Eg5 causes the formation of monoastral mitotic spindles, which leads to cell death. AZD4877 is a specific, potent inhibitor of Eg5. METHODS This was a Phase I, open-label, two-part study to evaluate the maximum tolerated dose (MTD) and safety and tolerability of AZD4877 in patients with advanced solid malignancies. In part A, the MTD of AZD4877, administered as three weekly 1-h intravenous (iv) infusions in a 28-day schedule, was determined by evaluating dose-limiting toxicity (DLT). In part B, the safety, tolerability, and pharmacokinetic profile of AZD4877 at the MTD were evaluated. RESULTS In part A, 29 patients received at least one dose of AZD4877 (5 mg, n = 4; 7.5 mg, n = 4; 10 mg, n = 3; 15 mg, n = 3; 20 mg, n = 3; 30 mg, n = 6; 36 mg, n = 3; 45 mg, n = 3). The MTD was defined as 30 mg, with the primary DLT being neutropenia. Although exposures appeared to be similar at the AZD4877 20 and 30 mg doses, dose reductions and omissions were higher in the 30-mg cohort; therefore, an intermediate dose, 25 mg, was evaluated in part B (n = 14). In part B, neutropenia remained the most commonly reported causally related adverse event. Exposure to AZD4877 was approximately dose proportional. Severity of neutropenia was related to exposure. CONCLUSION The MTD of AZD4877 given as a 1-h iv infusion on days 1, 8, and 15 of a 28-day cycle was 30 mg. At the selected 25 mg dose, AZD4877 had an acceptable safety profile.
Collapse
Affiliation(s)
- J R Infante
- Sarah Cannon Research Institute, Nashville, TN, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Dickson NR, Jones SF, Burris HA, Ramanathan RK, Weiss GJ, Infante JR, Bendell JC, McCulloch W, Von Hoff DD. A phase I dose-escalation study of NKP-1339 in patients with advanced solid tumors refractory to treatment. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2607] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Brail LH, Gray JE, Burris H, Simon GR, Cooksey J, Jones SF, Farrington D, Lam T, Jackson K, Chow K, Brandt JT, Infante JR. A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in combination with pemetrexed and carboplatin. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Arkenau H, Infante JR, Bendell JC, Burris HA, Rubin MS, Waterhouse DM, Jones GT, Spigel DR, Hainsworth JD. Lenalidomide in combination with gemcitabine in patients with untreated metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14640] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
26
|
Infante JR, Falchook GS, Lawrence DP, Weber JS, Kefford RF, Bendell JC, Kurzrock R, Shapiro G, Kudchadkar RR, Long GV, Burris HA, Kim KB, Clements A, Peng S, Yi B, Allred AJ, Ouellet D, Patel K, Lebowitz PF, Flaherty KT. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.cra8503] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Raefsky E, Spigel DR, Infante JR, Bendell JC, Jones SF, Lipman AJ, Trent D, Kawamura S, Greco FA, Hainsworth JD, Burris HA. Phase II study of NK012 in relapsed small cell lung cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7079] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Hart L, Burris HA, Infante JR, Jones SF, Spigel DR, Bendell JC. mTOR inhibitor everolimus (Ev) and IGFR inhibitor OSI-906 (OSI) for the treatment of patients (pts) with refractory metastatic colorectal cancer (mCRC): A Sarah Cannon Research Institute phase I trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14054] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Shih KC, Infante JR, Papadopoulos KP, Bendell JC, Tolcher AW, Burris HA, Beeram M, Jackson L, Arcos R, Westin EH, Farrington D, McGlothlin A, Hynes S, Leohr J, Brandt JT, Nasir A, Patnaik A. A phase I dose-escalation study of LY2523355, an Eg5 inhibitor, administered either on days 1, 5, and 9; days 1 and 8; or days 1 and 5 with pegfilgrastim (peg) every 21 days (NCT01214642). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2600] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Hoh C, Infante JR, Burris HA, Tarazi JC, Kim S, Rosbrook B, Reid TR. Axitinib inhibition of [18F] fluorothymidine (FLT) uptake in patients (pts) with colorectal cancer (CRC): Implications for cytotoxic chemotherapy combinations. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3591] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Cervantes A, Alsina M, Tabernero J, Infante JR, LoRusso P, Shapiro G, Paz-Ares LG, Falzone R, Hill J, Cehelsky J, White A, Toudjarska I, Bumcrot D, Meyers R, Hinkle G, Svrzikapa N, Sah DW, Vaishnaw A, Gollob J, Burris HA. Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3025] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
Donehower RC, Scardina A, Hill M, Bowman J, Newton RC, Liu X, Scherle P, Wang Q, Diamond S, Boer J, Lee F, Gau T, Burris HA, Bendell JC, Jones SF, Infante JR. A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3091] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Burris HA, Siu LL, Infante JR, Wheler JJ, Kurkjian C, Opalinska J, Smith DA, Antal JM, Gauvin JL, Gonzalez T, Adams LM, Bedard P, Gerecitano JF, Kurzrock R, Moore KN, Morris SR, Aghajanian C. Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3003] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Nathanson KL, Martin A, Letrero R, D'Andrea KP, O'Day S, Infante JR, Falchook GS, Millward M, Curtis CM, Ma B, Gagnon RC, Lebowitz PF, Long GV, Kefford RF. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8501] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Papadopoulos KP, Mendelson DS, Tolcher AW, Patnaik A, Burris HA, Rasco DW, Bendell JC, Gordon MS, Kato G, Wong H, Bomba D, Lee S, Gillenwater HH, Woo T, Infante JR. A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3075] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Sikic BI, Eckhardt SG, Gallant G, Burris HA, Camidge DR, Colevas AD, Jones SF, Messersmith WA, Wakelee HA, Li H, Kaminker PG, Morris S, Infante JR. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3008] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Limentani SA, Burris H, Anderson AP, Brail LH, Satonin D, Gueorguieva I, Jones S, Infante JR, Bendell JC. A phase I dose-escalation and pharmacokinetic (PK) evaluation of an oral AKT inhibitor, LY2503029 (LY). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e13575] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Thompson JA, Forero-Torres A, Heath EI, Ansell SM, Pal SK, Infante JR, De Vos S, Hamlin PA, Zhao B, Klussman K, Whiting NC. The effect of SGN-75, a novel antibody–drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): A phase I study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3071] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
39
|
Domínguez ML, Rayo JI, Serrano J, Sánchez R, Infante JR, García L, Durán C. [Paraneoplastic polymyositis associated with primary lung cancer: diagnosis with PET-CT]. Rev Esp Med Nucl 2011; 30:187-190. [PMID: 21342726 DOI: 10.1016/j.remn.2010.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/19/2010] [Revised: 10/06/2010] [Accepted: 11/05/2010] [Indexed: 05/30/2023]
Affiliation(s)
- M L Domínguez
- Servicio de Medicina Nuclear, Hospital Universitario Infanta Cristina, Badajoz, Spain.
| | | | | | | | | | | | | |
Collapse
|
40
|
Infante JR, Cohn AL, Reid TR, Edenfield WJ, Cescon T, Hamm JT, Tarazi JC, Kim S, Rosbrook B, Cartwright TH. A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.485] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
485 Background: Vascular endothelial growth factor receptor inhibitors, including axitinib (AG-013736), may be useful in treating patients with mCRC. The goals of this study were to estimate the objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and safety in patients with mCRC treated with mFOLFOX-6 combined with axitinib or bevacizumab or both. Methods: Patients with mCRC untreated with any systemic chemotherapy >12 months prior to enrollment, ECOG PS 0/1, adequate organ function, and controlled hypertension were eligible for this randomized, open-label, phase II study. Patients receiving prior treatment with antiangiogenic agents or those who were pregnant were ineligible. All patients received standard mFOLFOX-6 treatment and were randomized to receive either axitinib 5 mg (Arm A), or bevacizumab 5 mg/kg (Arm B), or axitinib 5 mg + bevacizumab 2 mg/kg (Arm C). Axitinib was administered orally twice daily. Efficacy was determined by RECIST criteria. Results: A total of 42, 43, and 41 patients were enrolled in Arms A, B, and C, respectively. The ORR was 29%, 49%, and 39% for Arms A, B, and C, respectively. Median PFS was 315 days, 350 days, and 377 days, with 1-year survival of 72%, 79%, and 80% for Arms A, B, and C, respectively. Discontinuations due to adverse events (AEs) were more common in Arm A (36%), than in Arms B (19%) or C (32%). More patients withdrew from Arm A (18%) than from Arms B (5%) or C 12%). The rates of grade 3 AEs were similar across arms, except for hypertension and fatigue which were more common in Arms A (15% and 12%) and C (21% and 29%) compared with Arm B (2% and 12%). Serious AEs were reported by 41%, 40%, and 56% of patients in Arms A, B, and C, respectively; the most common were gastrointestinal disorders (21%, 16%, 15%, respectively). Conclusions: In combination with mFOLFOX-6 chemotherapy, treatment with axitinib resulted in a lower ORR but comparable survival to bevacizumab and this did not appear to improve significantly in the presence of both agents. This result may have been affected by the higher numbers of discontinuations and withdrawals in Arm A compared with the other 2 arms. [Table: see text]
Collapse
Affiliation(s)
- J. R. Infante
- Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Center, Denver, CO; University of California, San Diego Moores Cancer Center, La Jolla, CA; Cancer Centers of the Carolinas, Greenville, SC; Berks Hem/Onc Associates, West Reading, PA; Norton Health Care, Louisville, KY; Pfizer Oncology, La Jolla, CA; US Oncology Pathways Task Force, The Woodlands, TX
| | - A. L. Cohn
- Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Center, Denver, CO; University of California, San Diego Moores Cancer Center, La Jolla, CA; Cancer Centers of the Carolinas, Greenville, SC; Berks Hem/Onc Associates, West Reading, PA; Norton Health Care, Louisville, KY; Pfizer Oncology, La Jolla, CA; US Oncology Pathways Task Force, The Woodlands, TX
| | - T. R. Reid
- Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Center, Denver, CO; University of California, San Diego Moores Cancer Center, La Jolla, CA; Cancer Centers of the Carolinas, Greenville, SC; Berks Hem/Onc Associates, West Reading, PA; Norton Health Care, Louisville, KY; Pfizer Oncology, La Jolla, CA; US Oncology Pathways Task Force, The Woodlands, TX
| | - W. J. Edenfield
- Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Center, Denver, CO; University of California, San Diego Moores Cancer Center, La Jolla, CA; Cancer Centers of the Carolinas, Greenville, SC; Berks Hem/Onc Associates, West Reading, PA; Norton Health Care, Louisville, KY; Pfizer Oncology, La Jolla, CA; US Oncology Pathways Task Force, The Woodlands, TX
| | - T. Cescon
- Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Center, Denver, CO; University of California, San Diego Moores Cancer Center, La Jolla, CA; Cancer Centers of the Carolinas, Greenville, SC; Berks Hem/Onc Associates, West Reading, PA; Norton Health Care, Louisville, KY; Pfizer Oncology, La Jolla, CA; US Oncology Pathways Task Force, The Woodlands, TX
| | - J. T. Hamm
- Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Center, Denver, CO; University of California, San Diego Moores Cancer Center, La Jolla, CA; Cancer Centers of the Carolinas, Greenville, SC; Berks Hem/Onc Associates, West Reading, PA; Norton Health Care, Louisville, KY; Pfizer Oncology, La Jolla, CA; US Oncology Pathways Task Force, The Woodlands, TX
| | - J. C. Tarazi
- Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Center, Denver, CO; University of California, San Diego Moores Cancer Center, La Jolla, CA; Cancer Centers of the Carolinas, Greenville, SC; Berks Hem/Onc Associates, West Reading, PA; Norton Health Care, Louisville, KY; Pfizer Oncology, La Jolla, CA; US Oncology Pathways Task Force, The Woodlands, TX
| | - S. Kim
- Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Center, Denver, CO; University of California, San Diego Moores Cancer Center, La Jolla, CA; Cancer Centers of the Carolinas, Greenville, SC; Berks Hem/Onc Associates, West Reading, PA; Norton Health Care, Louisville, KY; Pfizer Oncology, La Jolla, CA; US Oncology Pathways Task Force, The Woodlands, TX
| | - B. Rosbrook
- Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Center, Denver, CO; University of California, San Diego Moores Cancer Center, La Jolla, CA; Cancer Centers of the Carolinas, Greenville, SC; Berks Hem/Onc Associates, West Reading, PA; Norton Health Care, Louisville, KY; Pfizer Oncology, La Jolla, CA; US Oncology Pathways Task Force, The Woodlands, TX
| | - T. H. Cartwright
- Sarah Cannon Research Institute, Nashville, TN; Rocky Mountain Cancer Center, Denver, CO; University of California, San Diego Moores Cancer Center, La Jolla, CA; Cancer Centers of the Carolinas, Greenville, SC; Berks Hem/Onc Associates, West Reading, PA; Norton Health Care, Louisville, KY; Pfizer Oncology, La Jolla, CA; US Oncology Pathways Task Force, The Woodlands, TX
| |
Collapse
|
41
|
Messersmith WA, Falchook GS, Fecher LA, Gordon MS, Vogelzang NJ, DeMarini DJ, Peddareddigari VG, Xu Y, Bendell JC, Infante JR. Clinical activity of the oral MEK1/MEK2 inhibitor GSK1120212 in pancreatic and colorectal cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.246] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
246 Background: GSK1120212 is a reversible, highly selective allosteric inhibitor of MEK1/MEK2. The objectives of this phase I study are to define the maximum tolerated dose (MTD), and to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and response rate of GSK1120212 in advanced solid tumors. Cohorts of advanced chemoresistant pancreas (PC) and colorectal cancer (CRC) patients have been enrolled. Methods: GSK1120212 is given orally, once daily (QD). In this three-part study GSK1120212 was escalated to an MTD, was administered in selected tumor types to evaluate recommended phase II doses (RP2D), and was evaluated for minimum biological activity using PD assessments. Results: 202 patients (pts) have received ≥ 1 dose of GSK1120212, including 26 PC and 27 CRC pts. The MTD is 3 mg QD and the RP2D is 2 mg QD. Dose limiting toxicities are rash (N=2), diarrhea (N=1), central serous retinopathy (N=2) and are reversible. At 2 mg QD (N=68), the most common adverse events are rash (47% G1, 37% G2, 4% G3) and diarrhea (41% G1, 12% G2, 1% G3). There has been one event of retinal vein occlusion. GSK1120212 has a small peak:trough ratio of ∼ 2 and an effective half life of ∼ 4.5 days. Steady state is reached by ∼ day 15. In the 26 evaluable PC pts, 2 partial responses (PR) and 11 stable diseases (SD) have been observed. 1 PR is KRAS mutation positive and is ongoing at 28 weeks. Among the SD pts, 2 achieved ≥ 20% tumor reduction and at least 3 were on study for 16 weeks or longer. CA19-9 reduction ≥ 55% was observed in both PR and 3 SD pts, 1 of which remained on study for 40 weeks. Among the KRAS mutation positive CRC pts (n=12), 4 SD were observed. These pts were on study for 31, 28, 16, and 16 weeks. Among the KRAS mutation negative or status unknown pts (n=12), 2 SD were observed; no pt was on study for > 19 weeks. Among the B-RAF mutation positive pts (n=3), 2 SD were observed; both are still ongoing at >16 weeks. Conclusions: The RP2D is well tolerated. The long effective half life and small peak:trough ratio of GSK1120212 allow constant target inhibition within a narrow range of exposure. GSK1120212 demonstrates durable clinical activity in a subset of pts with PC or CRC. [Table: see text]
Collapse
Affiliation(s)
- W. A. Messersmith
- University of Colorado Cancer Center, Aurora, CO; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Pinnacle Oncology of Arizona, Scottsdale, AZ; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; GlaxoSmithKline Research and Development, Collegeville, PA; Sarah Cannon Research Institute, Nashville, TN
| | - G. S. Falchook
- University of Colorado Cancer Center, Aurora, CO; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Pinnacle Oncology of Arizona, Scottsdale, AZ; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; GlaxoSmithKline Research and Development, Collegeville, PA; Sarah Cannon Research Institute, Nashville, TN
| | - L. A. Fecher
- University of Colorado Cancer Center, Aurora, CO; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Pinnacle Oncology of Arizona, Scottsdale, AZ; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; GlaxoSmithKline Research and Development, Collegeville, PA; Sarah Cannon Research Institute, Nashville, TN
| | - M. S. Gordon
- University of Colorado Cancer Center, Aurora, CO; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Pinnacle Oncology of Arizona, Scottsdale, AZ; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; GlaxoSmithKline Research and Development, Collegeville, PA; Sarah Cannon Research Institute, Nashville, TN
| | - N. J. Vogelzang
- University of Colorado Cancer Center, Aurora, CO; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Pinnacle Oncology of Arizona, Scottsdale, AZ; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; GlaxoSmithKline Research and Development, Collegeville, PA; Sarah Cannon Research Institute, Nashville, TN
| | - D. J. DeMarini
- University of Colorado Cancer Center, Aurora, CO; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Pinnacle Oncology of Arizona, Scottsdale, AZ; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; GlaxoSmithKline Research and Development, Collegeville, PA; Sarah Cannon Research Institute, Nashville, TN
| | - V. G. Peddareddigari
- University of Colorado Cancer Center, Aurora, CO; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Pinnacle Oncology of Arizona, Scottsdale, AZ; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; GlaxoSmithKline Research and Development, Collegeville, PA; Sarah Cannon Research Institute, Nashville, TN
| | - Y. Xu
- University of Colorado Cancer Center, Aurora, CO; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Pinnacle Oncology of Arizona, Scottsdale, AZ; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; GlaxoSmithKline Research and Development, Collegeville, PA; Sarah Cannon Research Institute, Nashville, TN
| | - J. C. Bendell
- University of Colorado Cancer Center, Aurora, CO; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Pinnacle Oncology of Arizona, Scottsdale, AZ; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; GlaxoSmithKline Research and Development, Collegeville, PA; Sarah Cannon Research Institute, Nashville, TN
| | - J. R. Infante
- University of Colorado Cancer Center, Aurora, CO; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Pinnacle Oncology of Arizona, Scottsdale, AZ; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; GlaxoSmithKline Research and Development, Collegeville, PA; Sarah Cannon Research Institute, Nashville, TN
| |
Collapse
|
42
|
Tolcher AW, Bendell JC, Patnaik A, Papadopoulos K, Bellew KM, Cox DS, Xu Y, Burris HA, Le N, Infante JR. A phase Ib study of the MEK inhibitor GSK1120212 combined with gemcitabine in patients with solid tumors: Interim results. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.278] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
278 Background: GSK1120212 (212) is a reversible, allosteric inhibitor of MEK1/MEK2. The objectives of this open-label, single-arm study are to evaluate the safety, pharmacokinetics (PK), and anti-tumor activity of 212 + gemcitabine (gem), and to determine the recommended phase II regimen (RP2R) in patients (pts) with advanced solid tumors. Methods: 212 (1-2.5mg) is given continuously, orally, once daily. Gem (1,000mg/m2) is infused on days 1, 8, and 15 every 28 days. Doses are escalated to the maximum tolerated dose (MTD) and followed by an expansion cohort to confirm the RP2R tolerability. Results: 28 pts received ≥ 1 dose of 212 + gem, including 8 pancreatic, 6 breast, and 4 non-small cell lung (NSCLC) cancer pts. The MTD and RP2R is 2mg 212 + 1,000mg/m2 gem. Dose-limiting toxicities (DLTs) are G3/G4 febrile neutropenia (n=2), G3 AST elevation (n=2), and G2 uveitis (n=1). 16 serious adverse events (SAEs) were reported; 5 were considered to be related to study drugs (1 pneumonitis, 3 febrile neutropenia, 1 dyspnea). All DLTs and SAEs have resolved. The most common AEs at the RP2R (n=18) were rash (78%), fatigue (67%), thrombocytopenia (61%), neutropenia (50%), decreased appetite (50%), nausea (44%), diarrhea and constipation (39%); all ≤ G2 except thrombocytopenia (17% ≥ G3) and neutropenia (33% ≥ G3). Co-administration did not affect the PK profiles of 212 or gem. 25 pts had measurable disease at baseline. 1 pancreatic cancer pt with previous radiotherapy and 2 cycles of gem achieved a partial response and stayed on study for 6 months. 3 additional pancreatic cancer pts reported stable disease; 2 of which were on the study for 3.5-5 months and the third pt continues in the study. 1 triple-negative breast cancer pt, refractory to chemotherapy, and 1 parotid cancer pt experienced a complete response of their target lesions. Conclusions: 212 + gem is tolerable with an acceptable safety profile in this pt population, with evidence of clinical activity in pancreatic cancer. A randomized phase II study in previously untreated patients with metastatic pancreatic cancer is underway to investigate the clinical activity of this combination. [Table: see text]
Collapse
Affiliation(s)
- A. W. Tolcher
- The START Center for Cancer Care, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline Research and Development, Collegeville, PA
| | - J. C. Bendell
- The START Center for Cancer Care, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline Research and Development, Collegeville, PA
| | - A. Patnaik
- The START Center for Cancer Care, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline Research and Development, Collegeville, PA
| | - K. Papadopoulos
- The START Center for Cancer Care, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline Research and Development, Collegeville, PA
| | - K. M. Bellew
- The START Center for Cancer Care, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline Research and Development, Collegeville, PA
| | - D. S. Cox
- The START Center for Cancer Care, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline Research and Development, Collegeville, PA
| | - Y. Xu
- The START Center for Cancer Care, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline Research and Development, Collegeville, PA
| | - H. A. Burris
- The START Center for Cancer Care, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline Research and Development, Collegeville, PA
| | - N. Le
- The START Center for Cancer Care, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline Research and Development, Collegeville, PA
| | - J. R. Infante
- The START Center for Cancer Care, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; GlaxoSmithKline Research and Development, Collegeville, PA
| |
Collapse
|
43
|
Borad MJ, Chiorean EG, Molina JR, Mita AC, Infante JR, Schelman WR, Traynor AM, Vlahovic G, Mendelson DS, Reddy SG. Clinical benefits TH-302, a tumor-selective, hypoxia-activated prodrug, and gemcitabine in first-line pancreatic cancer (PanC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.265] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
265 Background: Gemcitabine (G) is the standard treatment for first- line PanC. PanC is one of the most hypoxic solid tumors. TH-302 is an inert prodrug of brominated isophosphoramide mustard and undergoes selective activation in deep hypoxia. As a single agent, tumor responses were reported in patients (pts) with metastatic melanoma, SCLC, and head/neck cancer at TH-302 weekly doses of 480-575 mg/m2. Methods: Eligible pts for the PanC expansion of this phase I/II study ( NCT00743379 ) had ECOG <1, locally advanced or metastatic PanC previously untreated with systemic chemotherapy other than adjuvant G, 5FU, and/or radiation. IV TH-302 was dosed at 240-575 mg/m2 (240 or 340 in expansion) with standard dose G (1000 mg/m2) on days 1, 8 and 15 of a 28-day cycle. Serum protein and microRNA hypoxia biomarkers were analyzed at baseline, start of cycle 3 and end of study. Results: 46 PanC subjects (12 locally advanced, 34 distant mets); median age: 63 (range 41-83); 24 male; ECOG 0/1 in 29/17 pts; RECIST response rate (RR) of 21%, median PFS of 6.1 mo (95%CI 4.8, 7.7) and median survival of 11.4 mo (95%CI 6.0, not reached) were observed. RR was 23% with median survival of 7.4 mo in pts with distant mets. 52% of pts had a >50% decrease in CA19-9. Common adverse events were skin or mucosal toxicity, nausea, fatigue and vomiting; most grade 1/2. Grade 3/4 neutropenia, thrombocytopenia and anemia in 68%, 64%, and 20% of pts respectively. The dose intensities at 240 mg/m2 and 340 mg/m2 were similar and related to hematologic toxicities. Skin toxicities were less common at 240 mg/m2. A TH-302 dose response was present with higher RR and PFS at 340 mg/m2. Initial serum hypoxia biomarkers did not identify a preferential pt population. Conclusions: The activity and clinical benefits of the combination of TH-302 with G in first line PanC are promising as compared to previous studies of G alone. TH-302 adds to the hematologic toxicity of G, but the regimen is well tolerated. The safety and activity provided rationale for comparing TH-302 plus G versus G alone in a randomized phase II trial ( NCT01144455 ) and indicate TH-302 may complement G by penetrating into the hypoxic regions of the PanC tumors where activation induces cytotoxicity. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. J. Borad
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - E. G. Chiorean
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - J. R. Molina
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - A. C. Mita
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - J. R. Infante
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - W. R. Schelman
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - A. M. Traynor
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - G. Vlahovic
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - D. S. Mendelson
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - S. G. Reddy
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| |
Collapse
|
44
|
Peacock NW, Jones SF, Yardley DA, Bendell JC, Infante JR, Murphy PB, Burris HA. Abstract P5-06-06: The Safety and Tolerability of Panobinostat (LBH589) in Combination with Capecitabine +/− Lapatinib: A Phase I Study in HER2+ Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p5-06-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Panobinostat is a histone deacetylase (HDAC) inhibitor, for which in vitro studies have suggested activity in breast cancer lines. This phase I study was designed to assess the safety, tolerability, and efficacy of panobinostat in combination with lapatinib and capecitabine in 3 parts. Part 1, for which we have previously reported findings (Peacock et al, ASCO 2010), established the maximum tolerated dose (MTD) of panobinostat (30mg twice weekly) in combination with capecitabine (1000mg/m2 BID). Part 2, reported here, was designed to assess the QTc prolongation and overall toxicity of panobinostat in combination with lapatinib in patients with HER2+ breast cancer. Part 3 will assess the tolerability and efficacy of the triplet combination based on doses defined in Parts 1 and 2. Method: Patients aged ≥18 years with incurable, locally recurrent or metastatic HER2+ breast cancer were eligible. Additional eligibility criteria included: < 3 prior treatments in the metastatic setting; ECOG PS 0-1; measurable disease by RECIST; no impairment of cardiac function; no prior treatment with HDAC inhibitors; informed consent. Lapatinib doses of 1000mg daily were administered with panobinostat doses of 15mg and 20mg three times weekly, following 1 week of 2 doses of panobinostat alone to assess QTc prolongation. Cycles were repeated every 21 days until disease progression or toxicity warranted drug discontinuation. Patients were reevaluated for response every 2 cycles.
Results: 5 female patients with HER2+ metastatic breast cancer were accrued to Part 2, with a median age of 66 years (range: 64 — 67); 80% of patients were ECOG PS 0. To date, patients have received 17 cycles of treatment (median 4 cycles), and 2 patients have stable disease (progression1, unevaluable 1, and too early to assess 1), with one patient remaining on treatment. There have been no dose-limiting toxicities. One patient was hospitalized for grade 3 peripheral neuropathy (unrelated). No grade 2/3/4 toxicities have occurred in >1 patient; no QTc prolongation has been observed.
Conclusions: Our preliminary findings suggest that the combination of panobinostat and lapatinib is safe and tolerable. No QTc prolongation or cardiotoxicity has been observed. Part 3 will evaluate the triplet combination using the dosages established in Parts 1 and 2.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-06-06.
Collapse
Affiliation(s)
- NW Peacock
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville
| | - SF Jones
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville
| | - DA Yardley
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville
| | - JC Bendell
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville
| | - JR Infante
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville
| | - PB Murphy
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville
| | - HA. Burris
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville
| |
Collapse
|
45
|
Greco FA, Infante JR, Burris HA, Jones SF, Kolesar J, Gardner LR, Sportelli P, Bendell JC. Safety and pharmacokinetic (PK) study of perifosine plus capecitabine (P-CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14086] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Rodler ET, Infante JR, Siu LL, Smith DC, Sullivan D, Vlahovic G, Gomez-Navarro J, Liu G, Blakemore S, Thompson JA. First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3071] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, Ouellet D, Curtis M, Lebowitz PF, Falchook GS. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8503] [Citation(s) in RCA: 185] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Thompson DS, Patnaik A, Bendell JC, Papadopoulos K, Infante JR, Mastico RA, Johnson D, Qin A, O'Leary JJ, Tolcher AW. A phase I dose-escalation study of IMGN388 in patients with solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3058] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Lee P, Wong AF, Burris HA, Papadopoulos K, Sausville EA, Rosen PJ, Mendelson DS, Infante JR, Patnaik A, Gordon MS. Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (pts) with relapsed malignancies. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
La-Beck NM, Wu H, Infante JR, Jones SF, Burris HA, Keedy VL, Kodaira H, Ikeda S, Ramanathan RK, Zamboni W. The evaluation of gender on the pharmacokinetics (PK) of pegylated liposomal anticancer agents. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13003] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|